LYEL vs TGT · rev $6.0K vs P/E 17, rev $51.98B
Lyell Immunopharma Inc (LYEL) versus Target Corporation (TGT) — a side-by-side from cached financials, not a winner call.
Lyell Immunopharma Inc (LYEL) is a biotechnology company listed on US.
Target Corporation (TGT) is a discount stores company listed on NYSE. It is led by Michael J. Fiddelke.
Latest reported LYEL revenue for 2026-06-30 was $6.0K. Net income was -$68.9M. LYEL currently screens at market cap $143.5M.
Latest reported TGT revenue for 2026-08-01 was $51.98B. Net income was $2.66B. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
LYEL currently screens at market cap $143.5M. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
Not investment advice. Open the LYEL and TGT stock pages for the full models.
Not investment advice.